{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:27:04Z","timestamp":1785410824230,"version":"3.56.0"},"reference-count":90,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of targeted agents against leukemia driver mutations have revolutionized therapy for subsets of patients. In addition, the development of more effective and less toxic induction regimens with a backbone of venetoclax and hypomethylating agents is a real advance in therapy for older or less fit patients with AML. In this review, we will describe improved outcomes for alternate induction strategies, results with combinations of targeted agents and standard chemotherapy, and the important role of complete diagnostic testing and clinical trials to improve outcomes for patients with AML.<\/jats:p>","DOI":"10.1200\/edbk-25-473646","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:59:08Z","timestamp":1748980748000},"source":"Crossref","is-referenced-by-count":11,"title":["Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia"],"prefix":"10.1200","volume":"45","author":[{"given":"Maire","family":"Okoniewski","sequence":"first","affiliation":[{"name":"University of Kansas Medical Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Gonzalez Lugo","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara L.","family":"Lin","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_3_3_3_2","volume-title":"SEER*Explorer: An Interactive Website for SEER Cancer Statistics SEER Incidence Data, November 2023 Submission (1975-2021)","unstructured":"SEER*Explorer: An Interactive Website for SEER Cancer Statistics SEER Incidence Data, November 2023 Submission (1975-2021). https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000504"},{"key":"e_1_3_3_5_2","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates JW","year":"1973","unstructured":"Yates JW, Wallace HJ Jr, Ellison RR, et al: Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 57:485-488, 1973","journal-title":"Cancer Chemother Rep"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901409"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904544"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-172007"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614359"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00464-6"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4874"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.01.015"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00134-4"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010276"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03736"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003510"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106971"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.3425"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4600"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003717"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01546"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9628"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716863"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018886960"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301689"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01143-2"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133512"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26395"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.243"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0313"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2021.10.006"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00870-3"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1005659"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115494"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00106-5"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026700"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203683"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0917"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182969"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209558"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013687"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182642"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000429"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158518"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202801"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027217"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136120"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00338-1"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198541"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0903840"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.01.020"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPD7NR2RMNQDVF"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-869008"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008282"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025409"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01999-6"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.3762"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.263806"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716984"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200393"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187060"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01911"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003988"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199882"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164849"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041974"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-02578-7"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209592"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.09.025"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.05.011"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.05.016"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-172422"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-192042"},{"key":"e_1_3_3_81_2","unstructured":"Zeidner JLT Madanat Y Koenig K et al Phase 1b study of azacitidine venetoclax and revumenib in newly diagnosed older adults with NPM1 mutated or KMT2a rearranged AML: Interim results of dose escalation from the Beat Aml Consortium. HemaSphere"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01600"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004856"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0312-9"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02001-z"},{"key":"e_1_3_3_86_2","unstructured":"A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies. Jannssen Research & Development LLC: ClinicalTrials.gov"},{"key":"e_1_3_3_87_2","unstructured":"Richard Stone M: Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Na\u00efve AML. Dana-Farber Cancer Institute ClinicalTrials.gov"},{"key":"e_1_3_3_88_2","unstructured":"Doehner DH: Phase III Study of Induction and Consolidation Chemotherapy with Venetoclax in Patients with Newly Diagnosed AML or MDS-EB-2. University of Ulm: ClinicalTrials.gov"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198218"},{"key":"e_1_3_3_90_2","volume-title":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (TUSCANY)","unstructured":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (TUSCANY). https:\/\/www.clinicaltrials.gov\/study\/NCT03850574"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205977"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-473646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:59:10Z","timestamp":1748980750000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-473646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/EDBK-25-473646"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-473646","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"e473646"}}